Expert Perspectives: Advancing Knowledge to Practice: Optimizing Severe Asthma Care in the Age of Biologics
Michael E. Wechsler, MD and Jonathan Corren, MD, discuss the clinical differentiation of asthma subgroups and the characterization of inflammatory pathways, as well as biomarkers for severe asthma and their application to clinical practice. They review the latest treatment options, focusing on new biologic-based targeted therapies, differentiating between biologic agents and their mechanism of action, as well as the latest safety and efficacy data of targeted therapy. They also discuss optimal treatment regimens based on asthma severity and biomarkers.
Format: Webcast
Time to Complete: 1 hour
Released: December 31, 2018
Expires: December 30, 2019
MAXIMUM CREDITS
1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour
1.00 / AANP Contact Hour
1.00 / CE for Pharmacists (0.10 CEUs)
1.00 / CNE Contact Hour
1.00 / AANP Contact Hour
1.00 / CE for Pharmacists (0.10 CEUs)
ACCREDITED PROVIDER
Provided by the Annenberg Center for Health Sciences at Eisenhower
COMMERCIAL SUPPORTER
This activity is supported by educational grants from GlaxoSmithKline, AstraZeneca, Sanofi Genzyme and Regeneron Pharmaceuticals.
PROGRAM DESCRIPTION
Michael E. Wechsler, MD and Jonathan Corren, MD, discuss the clinical differentiation of asthma subgroups and the characterization of inflammatory pathways, as well as biomarkers for severe asthma and their application to clinical practice. They review the latest treatment options, focusing on new biologic-based targeted therapies, differentiating between biologic agents and their mechanism of action, as well as the latest safety and efficacy data of targeted therapy. They also discuss optimal treatment regimens based on asthma severity and biomarkers.
Source: 